Pfizer's run at AstraZeneca is officially at an end. No more will-they-or-won't-they speculation, for at least a few months. What we're hearing now is a story of pride, prejudice, poor timing and miscalculation. CEOs and company boards are people, too, after all.
written on 27.05.2014
As the deal turns: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing
